Thermo Fisher Scientific & Moderna announce a 15-year partnership
Category: #health  By Pankaj Singh  Date: 2022-02-25
 | 
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Thermo Fisher Scientific & Moderna announce a 15-year partnership

Moderna Inc., a leading biotech company, and Thermo Fisher Scientific Inc., a leading science services provider, have reportedly announced a 15-year strategic partnership agreement. The collaboration will allow the committed large-scale production of Moderna’s COVID-19 vaccine Spikevax® in the United States along with other investigational mRNA medicines.

Thermo Fisher has been collaborating with Moderna over the past several years to bolster its development pipeline with clinical research as well as contract manufacturing services. This comprises rapid upscale of COVID-19 vaccine packaging and aseptic fill-finish services.

Under the terms of the extended agreement, Thermo Fisher will now offer committed capacity for different aseptic fill-finish services which include liquid and lyophilized filing. Additionally, the company will offer labeling, inspection, and final packaging services.

According to the Chief Technical Operations and Quality Officer of Moderna Juan Andres, Thermo Fisher is a trusted collaborator, and this long-term manufacturing partnership will allow the company to continue building its mRNA pipeline and platform.

Michel Lagarde, the Chief Operating Officer, and Executive Vice President of Thermo Fisher Scientific expressed that the strategic partnership expansion will enable Moderna to further leverage Thermo Fisher’s depth and scale of capabilities to continue transforming its mRNA platform and introduce new ground-breaking medicines to patients worldwide.

It should be noted that Moderna has been transforming from a company in a research stage that advance programs in mRNA to an enterprise with an assorted clinical portfolio of therapeutics and vaccines across seven modalities, an extensive intellectual property portfolio in sectors like lipid nanoparticle and mRNA formulation as well as a consolidated manufacturing facility that enables at-scale commercial and clinical production at unmatched speeds.

The company retains partnerships with a wide range of international and domestic commercial and government collaborators, which has enabled the pursuit of rapid scaling of manufacturing and breakthrough science.

Source credit:

https://finance.yahoo.com/news/moderna-thermo-fisher-scientific-announce-130000457.html



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

By Pankaj Singh

Rona Therapeutics Inc has reportedly acquired the global exclusive rights to the siRNA platform of delivery moiety and chemical modification from Sanofi S.A., in addition to four pre-clinical contenders for unrevealed ...

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

By Pankaj Singh

California-based toy manufacturing and entertainment company, Mattel, has recently signed a multi-year agreement with Elon Musk’s private spaceflight company, SpaceX.

T...

USHV partners with Willowbrook to provide quality cardiovascular care

USHV partners with Willowbrook to provide quality cardiovascular care

By Pankaj Singh

US Heart & Vascular (USHV) is reportedly partnering with Willowbrook Cardiovascular Associates to offer quality cardiovascular care in the Houston market.

USHV has a strong ma...